List of Syndros drug patents

Syndros is owned by Benuvia.

Syndros contains Dronabinol.

Syndros has a total of 4 drug patents out of which 0 drug patents have expired.

Syndros was authorised for market use on 23 March, 2017.

Syndros is available in solution;oral dosage forms.

The generics of Syndros are possible to be released after 06 August, 2028.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9345771 BENUVIA Oral cannabinoid formulations
Aug, 2028

(5 years from now)

US8222292 BENUVIA Liquid cannabinoid formulations
Aug, 2028

(5 years from now)

US10265293 BENUVIA Oral cannabinoid formulations
Aug, 2028

(5 years from now)

US11253472 BENUVIA Oral cannabinoid formulations
Aug, 2028

(5 years from now)

Drugs and Companies using DRONABINOL ingredient

Market Authorisation Date: 23 March, 2017

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of SYNDROS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in